NR 546 Week 6 Addiction Medication
Table QUESTIONS AND CORRECT
DETAILED ANSWERS WITH RATIONALES
(VERIFIED ANSWERS) |ALREADY GRADED
A+
Drug Name Indication Half-life (T1/2), Notable Side Effects Initial Dosing Considerations
Neurotransmitter(s) Metabolism (CYP (link to NT or Specific lifespan
Affected 450 enzyme) affected brain circuit) considerations (age,
Target Symptoms pregnancy, breastfeeding)
Buprenorphine Indication: Half-life: 24-42 • Headache, Initial dosing: Day 1: 8 mg Day
(Subutex) • Maintenance hours CYP450: constipation, nausea 2: 12-16 mg Days 3-7: Increase
treatment of opioid CYP3A4 • Oral hypoesthesia, in increments of 4 mg,
dependence glossodynia maximum 32 mg
• Maintenance • Orthostatic Considerations:
treatment of opioid hypotension • Use with caution in elderly
dependence in • Implant specific: and those with cardiac
patients who have insertion site pain, impairment
achieved and pruritis, erythema
sustainced
, NR 546 Week 6 Addiction Medication
Table QUESTIONS AND CORRECT
DETAILED ANSWERS WITH RATIONALES
(VERIFIED ANSWERS) |ALREADY GRADED
A+
prolonged clinical • Respiratory • May be preferable to
stability on low-to- depression methadone in pregnant
moderate doses of • Hepatotoxicity women
a transmucosal • Neonatal withdrawal may
buprenorphine occur
containing product • Drug is found in breast milk,
• Moderate to recommended to DC drug or
severe opioid use bottle feed
disorder in patients • Safety and efficacy has not
who have initiated been established for children
treatment with a and adolescents.
transmucosal
buprenorphine
containing product,
followed by dose
adjustment for a
Table QUESTIONS AND CORRECT
DETAILED ANSWERS WITH RATIONALES
(VERIFIED ANSWERS) |ALREADY GRADED
A+
Drug Name Indication Half-life (T1/2), Notable Side Effects Initial Dosing Considerations
Neurotransmitter(s) Metabolism (CYP (link to NT or Specific lifespan
Affected 450 enzyme) affected brain circuit) considerations (age,
Target Symptoms pregnancy, breastfeeding)
Buprenorphine Indication: Half-life: 24-42 • Headache, Initial dosing: Day 1: 8 mg Day
(Subutex) • Maintenance hours CYP450: constipation, nausea 2: 12-16 mg Days 3-7: Increase
treatment of opioid CYP3A4 • Oral hypoesthesia, in increments of 4 mg,
dependence glossodynia maximum 32 mg
• Maintenance • Orthostatic Considerations:
treatment of opioid hypotension • Use with caution in elderly
dependence in • Implant specific: and those with cardiac
patients who have insertion site pain, impairment
achieved and pruritis, erythema
sustainced
, NR 546 Week 6 Addiction Medication
Table QUESTIONS AND CORRECT
DETAILED ANSWERS WITH RATIONALES
(VERIFIED ANSWERS) |ALREADY GRADED
A+
prolonged clinical • Respiratory • May be preferable to
stability on low-to- depression methadone in pregnant
moderate doses of • Hepatotoxicity women
a transmucosal • Neonatal withdrawal may
buprenorphine occur
containing product • Drug is found in breast milk,
• Moderate to recommended to DC drug or
severe opioid use bottle feed
disorder in patients • Safety and efficacy has not
who have initiated been established for children
treatment with a and adolescents.
transmucosal
buprenorphine
containing product,
followed by dose
adjustment for a
